Bristol-Myers Squibb (BMS) and bluebird bio announced that the Food and Drug Administration (FDA) has approved the marketing of Abecma (idecabtagene vicleucel), a chimeric antigen receptor T (CAR-T) cell immunotherapy targeting BRead More…
Science Translational Medicine: New Costimulatory Signal Enables CAR-T to Show Potential of Treating Solid Tumor
T cells expressing chimeric antigen receptors (CAR-T) are one of the major breakthroughs in the field of cancer treatment in recent years, and they have achieved excellent efficacy in the treatment ofRead More…
CAR-T Therapy Evolution—Application of Non-viral Vector and Gene Knock-in Technology
As a precision targeted therapy for tumor treatment, CAR-T (chimeric antigen receptor t-cell immunotherapy) has achieved promising results in clinical tumor treatment with optimization and improvement in recent years. It is cutting-edgeRead More…
The Potential of CAR-Macrophages Therapy in Novel Coronavirus Clearance
At present, the vaccine research for the Coronavirus Disease (COVID-19) is in progress, but the drug research and development for severe COVID-19 remains a thorny scientific problem. Up to now, there isRead More…
FDA Approves the First IND Application for Universal CAR-T Therapy Derived from iPSC
On July 9th, Fate Therapeutics announced that U.S. Food and Drug Administration has approved the first IND application for iPSC-derived allogeneic CAR-T cell therapy FT819 for the treatment of recurrent/refractory B-cell malignant tumors,Read More…
HLA System and HLA Typing
The human leukocyte antigen (HLA) system or complex is a group of highly polymorphic genomes on chromosomes that encode major histocompatibility complex (MHC) proteins which are expressed on the surface of cellRead More…
PNAS: Targeting Tox and Tox2 is Expected to Improve the Treatment of Solid Tumors by CAR-T Cell Immunotherapy.
Ten years ago, scientists announced the development of cancer immunotherapy called chimeric antigen receptor-T cell (CAR-T) therapy: genetically modifying T cells from patients to make them powerful anti-tumor effects, and then infusingRead More…
For the first time! Production of CAR-T cells expressing anti-CD19 without virus and plasmid
Recently, it was announced that LineaRx (a part of Applied DNA Science), a company specializing in next-generation biotherapy, has achieved anti-CD19-CAR (chimeric antigen receptor) expression on human T cells through its proprietaryRead More…
Scientists Found a Novel Strategy to Resist T Cell Failure In CAR-T Cell Therapy
More and more cancer patients are receiving a promising new treatment called CAR-T cell therapy. In this treatment, the patient’s own T cells are removed from the body and genetically modified toRead More…
Scientists Reveal the Molecular Mechanism of CAR-T Cells in Anti-cancer Effect
Scientists have been hugely successful in developing a new type of anti-cancer therapy, immunotherapy, over the past decade, a treatment that attacks cancer cells by activating the body’s autoimmune system. One of theRead More…